Anthestos Pharmaceuticals is an early-stage biotech spin-off from the University of Patras developing crRASP, a novel pluripotent retinoid-polyamine conjugate for dermatological conditions. crRASP offers retinoid-class efficacy in preclinical models,  anti-inflammatory, anti-angiogenic, keratinocyte-modulating,  without the irritation, phototoxicity, or teratogenicity that limit current topical retinoids. Backed by 15+ years of peer-reviewed research and protected by new-generation IP covering the crystalline form and mild, efficient, cost-effective and readily scalable synthesis, the company is advancing crRASP toward clinical readiness through a capital-efficient virtual biotech model. Initial focus: topical treatment of psoriasis.

Anthestos Pharmaceuticals

Org chart

Teams

Offices